Yun Beom Sang - Search Results

Year	Number of Results
2021	2
2022	3
2023	3
2024	3

1

Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach.

Kim CG, Sang YB, Lee JH, Chon HJ. Kim CG, et al. Among authors: sang yb. Int J Mol Sci. 2021 Jul 27;22(15):8035. doi: 10.3390/ijms22158035. Int J Mol Sci. 2021. PMID: 34360800 Free PMC article. Review.

2

The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges.

Sang YB, Kim JH, Kim CG, Hong MH, Kim HR, Cho BC, Lim SM. Sang YB, et al. Front Oncol. 2022 Mar 3;12:811247. doi: 10.3389/fonc.2022.811247. eCollection 2022. Front Oncol. 2022. PMID: 35311091 Free PMC article. Review.

3

Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma.

Song YS, Yang H, Kang B, Cheon J, Kim I, Kim H, Lee WS, Sang YB, Jung S, Lim HY, Gaillard VE, Kim C, Chon HJ. Song YS, et al. Among authors: sang yb. Liver Cancer. 2023 May 25;13(1):89-98. doi: 10.1159/000531182. eCollection 2024 Feb. Liver Cancer. 2023. PMID: 38344445 Free PMC article.

4

High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma.

Sang YB, Yang H, Lee WS, Lee SJ, Kim SG, Cheon J, Kang B, Kim CW, Chon HJ, Kim C. Sang YB, et al. Cancers (Basel). 2022 Dec 3;14(23):5985. doi: 10.3390/cancers14235985. Cancers (Basel). 2022. PMID: 36497467 Free PMC article.

5

Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c-MET Amplification.

Sang YB, Kim G, Hwang S, Kang H, Chon HJ. Sang YB, et al. J Clin Transl Hepatol. 2023 Jun 28;11(3):747-750. doi: 10.14218/JCTH.2022.00212. Epub 2022 Aug 31. J Clin Transl Hepatol. 2023. PMID: 36969903 Free PMC article.

6

Impact of Coronavirus Disease 2019 on Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab.

Sang YB, Lee C, Kim SG, Lee B, Kang B, Kim C, Chon HJ. Sang YB, et al. J Clin Med. 2024 Feb 27;13(5):1335. doi: 10.3390/jcm13051335. J Clin Med. 2024. PMID: 38592150 Free PMC article.

7

Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis.

Cheon J, Lee CK, Sang YB, Choi HJ, Kim MH, Ji JH, Ko KH, Kwon CI, Kim DJ, Choi SH, Kim C, Kang B, Chon HJ. Cheon J, et al. Among authors: sang yb. Ther Adv Med Oncol. 2021 Aug 7;13:17588359211035983. doi: 10.1177/17588359211035983. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34394748 Free PMC article.

8

High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma.

Kim Y, Yang H, Lee WS, Cheon J, Sang YB, Kang B, Chon HJ, Kim C. Kim Y, et al. Among authors: sang yb. J Cancer. 2023 Apr 2;14(6):935-942. doi: 10.7150/jca.81384. eCollection 2023. J Cancer. 2023. PMID: 37151396 Free PMC article.

9

Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for more than 1 Year.

Kim Y, Kim JS, Kang B, Kim I, Kim H, Lee WS, Sang YB, Jung S, An C, Kim C, Chon HJ. Kim Y, et al. Among authors: sang yb. Cancer Res Treat. 2024 May 27. doi: 10.4143/crt.2024.237. Online ahead of print. Cancer Res Treat. 2024. PMID: 38810969 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

9 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year